After an impressive 953% trailing-10-year total return, investors are ready to tackle the next milestone.

This company has a habit of beating the market over long periods.

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Bristow Group, a global aviation services provider to offshore energy firms, reported a notable insider sale in its latest SEC filing.

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Buffett's actions suggest that we could be knee-deep in investment opportunities soon.

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

It is a new era at Berkshire Hathaway.

While this young and intriguing EV stock has immense upside, it comes with too much risk for many investors -- here's why.

Both companies benefit from the momentum in custom AI chips.

Both stocks provide much more upside than downside at current prices.

Microsoft's valuation is at its lowest point since the 2022 bear market.

These three tech stocks look like long-term winners.

Here's how to participate as the world slowly shifts away from dirtier energy sources and toward cleaner ones.